TIGIT/CD155在肝细胞癌发生发展中的研究进展  

Research progress of TIGIT/CD155 in the occurrence and development of hepatocellular carcinoma

作　　者：王俊旗 徐锋[1] WANG Jun-qi;XU Feng(Department of General Surgery,Shengjing Hospital of China Medical University,Shenyang,Liaoning 110004,China)

机构地区：[1]中国医科大学附属盛京医院普通外科,辽宁沈阳110004

出　　处：《中国临床研究》2022年第11期1592-1595,共4页Chinese Journal of Clinical Research

基　　金：辽宁省自然科学基金项目(20180551193,2020-MS-181);盛京医院345人才工程计(40B)。

摘　　要：肝细胞癌(HCC)是全球范围内致死率最高的恶性肿瘤之一,其发生发展与病毒性肝炎及肝纤维化/肝硬化密不可分。在HCC的发生发展过程中,新型免疫检查点TIGIT/CD155发挥着免疫抑制作用,导致机体免疫失调。本文对TIGIT/CD155的功能及其在HCC发生发展中的作用机制作一综述,以期探究该免疫检查点在HCC免疫治疗中的应用前景。Hepatocellular carcinoma(HCC)is one of the most lethal malignant tumors in the world.Its occurrence and development are closely related to viral hepatitis and liver fibrosis/cirrhosis.During the occurrence and development of HCC,TIGIT/CD155,a new immune checkpoint,plays an immunosuppressive role,leading to immune imbalance.This paper reviews the function of TIGIT/CD155 and its mechanism in the occurrence and development of HCC,to explore the application prospect of TIGIT/CD155 in HCC immunotherapy.

关 键 词：TIGIT CD155 免疫检查点 肝细胞癌 免疫治疗 病毒性肝炎 肝纤维化 肝硬化 

分 类 号：R735.7[医药卫生—肿瘤]